Purple biotech reports third quarter 2023 financial results

Initial activity in head and neck cancer demonstrated in nt219 phase 1 /2 do s e escalation study patients ' e nrollment in the phase 2 randomized cm24 pancreatic cancer t rial a head of t imelines c ash r unway extended to 2h 2025 through recent financing
PPBT Ratings Summary
PPBT Quant Ranking